Narrow Results

Critical care medicine is a medical specialty engaging the diagnosis and treatment of critically ill patients who have or are likely to have life-threatening organ failure. Sepsis, a life-threatening condition that arises when the body responds to infection, is currently the major cause of death in intensive care units (ICU). Although progress has been made in understanding the pathophysiology of sepsis, many drawbacks in sepsis treatment remains unresolved. For example, antimicrobial resistance, controversial of glucocorticoids use, prolonged duration of ICU care and the subsequent high cost of the treatment. Recent years have witnessed a growing trend of applying traditional Chinese medicine (TCM) in sepsis management. The TCM application emphasizes use of herbal formulation to balance immune responses to infection, which include clearing heat and toxin, promoting blood circulation and removing its stasis, enhancing gastrointestinal function, and strengthening body resistance. In this paper, we will provide an overview of the current status of Chinese herbal formulations, single herbs, and isolated compounds, as an add-on therapy to the standard Western treatment in the sepsis management. With the current trajectory of worldwide pandemic eruption of newly identified Coronavirus Disease-2019 (COVID-19), the adjuvant TCM therapy can be used in the ICU to treat critically ill patients infected with the novel coronavirus.

Artemisinin and its derivatives (ARTs), due to their potent antimalarial activities, are widely used as frontline antimalarials across the world. Although the large-scale deployment of ARTs has significantly contributed to a substantial decline in malaria deaths, the global malaria burden is still high. New antimalarial treatments need to be developed to manage the growing artemisinin resistance. Understanding the status of ART development is crucial for developing strategies for new alternatives and identifying opportunities to develop ART-based treatments. This study sampled ART clinical trials from the past two decades to gain an overview of the global ART-development landscape. A total of 768 trials were collected to analyze the disease focuses, activity trends, development status, geographic distribution, and combination treatment profiles of ART trials. The findings highlighted the constant focus of ARTs on malaria, the evolving combination research focus, the distinctions between ART development preferences across global regions, the urgent demands for treatments for artemisinin-resistant malaria, and the unavoidable need to consider ART combinations in the development of new antimalarials.

Ferroptosis, an iron-dependent cell death mechanism driven by an accumulation of lipid peroxides on cellular membranes, has emerged as a promising strategy to treat various diseases, including cancer. Ferroptosis inducers not only exhibit cytotoxic effects on multiple cancer cells, including drug-resistant cancer variants, but also hold potential as adjuncts to enhance the efficacy of other anti-cancer therapies, such as immunotherapy. In addition to synthetic inducers, natural compounds, such as artemisinin, can be considered ferroptosis inducers. Artemisinin, extracted from Artemisia annua L., is a poorly water-soluble antimalarial drug. For clinical applications, researchers have synthesized various water-soluble artemisinin derivatives such as dihydroartemisinin, artesunate, and artemether. Artemisinin and artemisinin derivatives (ARTEs) upregulate intracellular free iron levels and promote the accumulation of intracellular lipid peroxides to induce cancer cell ferroptosis, alleviating cancer development and resulting in strong anti-cancer effects in vitro and in vivo. In this review, we introduce the mechanisms of ferroptosis, summarize the research on ARTEs-induced ferroptosis in cancer cells, and discuss the clinical research progress and current challenges of ARTEs in anti-cancer treatment. This review deepens the current understanding of the relationship between ARTEs and ferroptosis and provides a theoretical basis for the clinical anti-cancer application of ARTEs in the future.

Big Pharma in legal battles for monopoly prices in India.

Aeterna Zentaris: Phase 3 Data for Perifosine in Colorectal Cancer Presented at ASCO Meeting.

Vietnam partners with Australia to combat TB.

Artemisinin resistance emerged on Thai-Myanmar border 'years ago'.

Research and License agreements between National Cheng Kung University and Novo Nordisk A/S.

SINGAPORE – NUS Researchers Uncover Potent Parasite-killing Mechanism of Nobel Prize-Winning Anti-Malarial Drug.

SINGAPORE – Robotic Glove Invented by NUS Researchers Helps Patients Restore Hand Movements.

UNITED STATES – Study Reveals Environment, Behavior Contribute to Some 80 Percent of Cancers.

UNITED STATES – Probing the Mystery of How Cancer Cells Die.

UNITED STATES – Liver Hormone Works Through Brain's Reward Pathway to Reduce Preference for Sweets & Alcohol.

UNITED STATES – How Three Genes You've Never Heard of May Influence Human Fertility.

UNITED STATES – Researchers Find Link between Processed Foods and Autoimmune Diseases.

UNITED KINGDOM – Is Evolution More Intelligent Than We Thought?

UNITED KINGDOM – Unravelling the Genetics of Pregnancy and Heart Failure.

SWITZERLAND – New Global Framework to Eliminate Rabies.

CANADA – Droughts Hit Cereal Crops Harder Since 1980s.

TAIWAN – Discovery of Key Autophagy Terminator that Contributes to Cell Survival and Muscle Homeostasis.

JAPAN – Nanomaterial wrap for improved tissue imaging.

USA – Test strips for cancer detection get upgraded with nanoparticle bling.

SINGAPORE – A*STAR’s IMB discovers ELABELA protects against cardiovascular malformations in mice.

SINGAPORE – NUS scientists combine antimalarial drug with light sensitive molecules for promising treatment of cancer.

INDIA – A novel antifungal molecule discovered in bacteria.

MALAYSIA – Fermenting fish to reduce cholesterol.

China-Germany sci-tech cooperation continue to bring more opportunities.

Study reveals mechanism behind ginger’s warming effect on body.

Doctors in Guangzhou conduct 5G-assisted remote ultrasound scan.

China proposes major changes to pharmaceutical regulations.

Hangzhou attracts RMB1.5 billion investments in bio-pharmaceutical projects.

Genetic testing encouraged to prevent ovarian cancer.

New technology enables large-scale production of artemisinin for malaria.

Shanghai wants to develop top health innovation zone.

New synthetic biology research center launched in Shanghai.

Chinese scientists suggest new thoughts in lupus treatment.

Nineteen 10-substitued deoxoartemisinin derivatives and artemisinin with activity against D-6 strains of malarial falciparum designated as Sierra Leone are studied. We use molecular electrostatic potential maps in an attempt to identify key structural features of the artemisinins that are necessary for their activities and molecular docking to investigate the interaction with the molecular receptor (heme). Chemometric modeling: Principal Component Analysis (PCA), Hierarchical Cluster Analysis (HCA), K-Nearest Neighbor (KNN), Soft Independent Modeling of Class Analogy (SIMCA) and Stepwise Discriminant Analysis (SDA) are employed to reduce dimensionality and investigate which subset of descriptors are responsible for the classification between more active (MA) and less active (LA) artemisinins. The PCA, HCA, KNN, SIMCA and SDA studies showed that the descriptors LUMO (Lowest Unoccupied Molecular Orbital) energy, DFeO₁ (Distance between the O₁ atom from ligand and iron atom from heme), X1A (Average Connectivity Index Chi-1) and Mor15u (Molecular Representation of Structure Based on Electron Diffraction) code of signal 15, unweighted, are responsible for separating the artemisinins according to their degree of antimalarial activity. The prediction study was done with a new set of eight artemisinins by using the chemometric methods and five of them were predicted as active against D-6 strains of falciparum malaria. In order to verify if the key structural features that are necessary for their antimalarial activities were investigated for the interaction with the heme, we also carried out calculations of the molecular electrostatic potential (MEP) and molecular docking. MEP maps and molecular docking were analyzed for more active compounds of the prediction set.

Artemisinin is widely employed to treat malaria. A variety of experiments have been done to research the dissolution property of artemisinin in different solvents. To have an in-depth understanding of the property, it is essential to explore the dissolution property from molecular level with molecular dynamics (MD) simulation, which needs a satisfactory force field of artemisinin. Therefore in the research a quantum chemistry based force field was developed. The quantum chemical calculation at different levels was done and Hartree–Fock (HF) level calculation gives satisfactory results. The charge distribution was then determined successfully. The van der Waals (VDW) parameters of the C unit with sp³-C were tuned according to the difference between the dissolution enthalpy of artemisinin in ethanol and ethyl acetate. With the developed force field, MD method was employed to successfully simulate the dissolution property of artemisinin in different solvents. The simulation results show that artemisinin molecules tends to aggregate in water, while in the aqueous solution of ethanol, the same number of artemisinin molecules tends to disperse. Furthermore, simulation results show that 8 M ethyl acetate aqueous solution has better dissolution ability than 8 M ethanol aqueous. The simulation gave agreements with the experimental results.

Heme, resulting from hemoglobin digestion by the malaria parasite is one of the main target of antimalarial drugs like chloroquine and artemisinin. This later molecule contains a trioxane which is activated by the reduced form of heme to generate a strong alkylating agent able to react with heme itself. Taking advantage of these studies, we prepared new antimalarial drugs, trioxaquines, containing a trioxane motif covalently linked to an aminoquinoline.

Science-based innovation emerged from novel and discontinuous innovations which provoked irreversible yet significant changes in science and technology. This research investigated the commercialization process of artemisinin, a typical science-based innovation in China. Due to her research involvement with artimisinin (qinghaosu), Tu Youyou received the 2011 Lasker Award in clinical medicine and the 2015 Nobel Prize in Physiology or Medicine jointly with William C. Campbell and Satoshi Ōmura. In this paper, the authors reviewed the process of artemisinin’s innovation from labs in a research institute to its entrance into the market. Based on the research, we reached the following conclusions. First, during the process of science-based innovation, a “new technology platform” might be established and a series of applications might be invented. Second, the extensive cooperation among research institutions and companies played a vital role in the science-based innovation. Third, the science-based innovation emerged through multidisciplinary research teams as well as contacts among scientists with cross-fields expertise. Fourth, for science-based innovation, early research funding mainly relied on public funds. During the commercialization stage, corporate funding plays a major role. Fifth, a clear research objective, an overall planning, coordination, and the stability of policies were also important factors in the entire science-based innovation process.